Abstract
The parasite Cryptosporidium causes severe diarrheal disease that can be life-threatening, and effective treatments are sorely lacking. Recently, aspartyl proteases (ASP) have emerged as targets with significant therapeutic potential in several related parasites, resulting in the development of multiple potent leads. ASPs are critical to the proteolytic activation and maturation of secretory proteins that parasites rely on to invade, manipulate, and upon completion of their replication cycle, exit the host cells in which they reside. The Cryptosporidium genome encodes five ASPs, which have not been previously studied. Here, we explore two of these enzymes and in genetic experiments find one, CpASP2, to be essential to parasite growth. Conditional deletion of the gene encoding this protease leads to arrest at two distinct points in the lifecycle. Cell biological studies of the mutant phenotype demonstrate that CpASP2 is required for egress of both asexual merozoites and male gametes. Mutant parasites appear to complete intracellular development yet are paralyzed and incapable of responding to stimuli that trigger motility and egress in wild-type. Ablation of CpASP2 in infected mice leads to rapid parasite clearance, highlighting the promise of CpASP2 and likely additional related enzymes as multistage targets of therapy.